Riches in Zeneca drugs pipeline; The Investment Column
That looks churlish for a company which churned out a 15 per cent rise in underlying profits before exceptionals of pounds 1.01bn in the year to December. More so when you add in Zeneca's "aspirational target" of achieving 15 per cent a year average earnings growth over the next five years.
There was little to quibble about in last year's figures. More than 14 per cent of the underlying sales growth in the main pharmaceuticals business to pounds 2.44bn came from products launched in the past two years. The cost of developing and launching these products is holding back profits, up an underlying 6 per cent to pounds 757m in the division, but the prospects are encouraging. Casodex, the prostate cancer treatment, saw sales jump from pounds 10m to pounds 68m and now claims a 45 per cent share of the US prescriptions market. Arimidex, the breast cancer drug, managed pounds 20m sales from a standing start last year, while Accolate, Zeneca's delayed entry into the asthma market, is said to be doing better than Glaxo's rival Flovent.
The group is also excited about the prospects for Zomig, the migraine treatment acquired from Glaxo last year. News that Zomig has won its first official approval, from the UK, will pit it against Glaxo's rival Naramig product, which has also just gained its first clearance, from Sweden.
But this is a big market and both Zomig and the Seroquel schizophrenia drug to be launched later this year are set to achieve peak sales well in excess of pounds 200m.
These and other launches should tide the group over any temporary gap in drugs in late-stage trials, while further out, some of the 18 products in the development pipeline will come good. The company can also use its pounds 272m net cash to plug any holes: Zestril, the group's best-selling heart drug, was after all acquired from Merck.
Currency could hit this year's figures, so profits of pounds 1.1bn would put the shares on a heady forward multiple of 24, but by 1998 that could have fallen to 20, in line with SmithKline Beecham and Glaxo. Hold on.
- 1 The truth about 'girl things': Three cheers for Heather Watson's honesty
- 2 Man who held up 'hire me' sign at Waterloo station returns a year later with 'I'm hiring' sign
- 5 Men behaving badly: Urinating while standing, 'manspreading' and the gendering of selfishness
Nigel Farage: NHS might have to be replaced by private health insurance
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
French court convicts three over homophobic tweets, in case hailed as a 'significant victory' by LGBT rights campaigners
British Muslim school children suffering a backlash of abuse following Paris attacks
George Galloway condemns 'racist, Islamophobic, hypocritical rag' Charlie Hebdo at freedom of speech rally
Islamic history is full of free thinkers - but recent attempts to suppress critical thought are verging on the absurd
iJobs Money & Business
Negotiable: Recruitment Genius: A Tax Assistant is required to join a leading ...
£16000 - £25000 per annum: Recruitment Genius: This is an exciting opportunity...
£45000 - £47000 per annum + bonus + benefits: Ashdown Group: Java Developer / ...
£35000 - £38000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...